NEW YORK (GenomeWeb News) – Molecular diagnostics is gaining traction among clinicians and were the second-most popular type of test performed in the second quarter, according to a survey released today by investment bank Mizuho Securities.

In the survey of 262 physicians and laboratory personnel for clues about trends in clinical labs, Mizuho found that molecular testing made up 25 percent of all tests performed during the second quarter of this year, trailing only immunochemical tests, which made up 36 percent of all test conducted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.